| Outcome Measures: |
Primary: Whole-body insulin sensitivity, Change in insulin sensitivity from baseline, assessed using the hyperinsulinemic-euglycemic clamp (60 mU/m2/min), 4 weeks | Secondary: Adipose insulin sensitivity, Change from baseline free fatty acid level during the low-dose insulin phase of the hyperinsulinemic-euglycemic clamp (20 mU/m2/min), 4 weeks|Fasting glucagon, Change from baseline fasting glucagon, measured by blood sample, 4 weeks|Prandial glucagon secretion, Change from baseline glucagon area under the curve (AUC) during mixed meal tolerance test (MMTT), 4 weeks|Glucagon response to hypoglycemia, Change from baseline glucagon AUC after glucose nadir as measured during the hyperinsulinemic hypoglycemic clamp, 4 weeks|Resting energy expenditure (REE), Change from baseline REE as measured by indirect calorimetry, 4 weeks|Overnight growth hormone curve, Change from baseline growth hormone area under the curve (AUC) as measured overnight blood samples, 4 weeks|Overnight free-fatty acids (FFA) curve, Change from baseline FFA under the curve (AUC) as measured overnight blood samples, 4 weeks|% fat mass, Change from baseline % fat mass as measured by air displacement plethysmography, 4 weeks|% fat free mass, Change from baseline % fat free mass as measured by air displacement plethysmography, 4 weeks|Body weight, Change from baseline body weight as measured by scale, 4 weeks|Total daily insulin dose, Change from baseline total daily insulin dose as measured by pump record, 4 weeks|Total daily basal insulin dose, Change from baseline total daily basal insulin dose as measured by pump record, 4 weeks|Total daily bolus insulin dose, Change from baseline total daily bolus insulin dose as measured by pump record, 4 weeks|% Time in Range (TIR), Change from baseline %TIR (defined by % readings between 70mg/dL - 180 mg/dL \[3.9 - 10.0 mmol/L\]) as measured by continuous glucose monitoring, 4 weeks|% Time Below Range (TBR), Change from baseline %TBR (defined by % readings below 70mg/dL \[3.9mmol/L\]) as measured by continuous glucose monitoring, 4 weeks|% Time level 1 hyperglycemia, Change from baseline % time level 1 hyperglycemia (defined by glucose \> 180 mg/dL \[10 mmol/L\] and glucose ≤ 250 mg/dL \[13.9 mmol/L\]) as measured by continuous glucose monitoring, 4 weeks|% Time level 2 hyperglycemia, Change from baseline % time level 1 hyperglycemia (defined by glucose \> 250 mg/dL \[13.9 mmol/L\])) as measured by continuous glucose monitoring, 4 weeks|Glycemic variability, Change from glycemic variability as measured by continuous glucose monitoring, 4 weeks|Arterial stiffness, Change from baseline arterial stiffness as measured by carotid femoral pulse-wave velocity (cfPWV), 4 weeks|Arterial stiffness, Change from baseline arterial stiffness as measured by Augmentation index (AIx) by radial artery tonometry, 4 weeks | Other: Diabetes Treatment Satisfaction, Change from baseline diabetes treatment satisfaction, as measured by questionnaire, 4 weeks|% Time level 1 hypoglycemia, Change from baseline % time level 1 hypoglycemia (defined by glucose \< 70 mg/dL \[3.9 mmol/L\] and ≥ 54 mg/dL \[3.0 mmol/L\]) as measured by continuous glucose monitoring, 4 weeks|% Time level 2 hypoglycemia, Change from baseline % time level 2 hypoglycemia (defined by glucose \< 54 mg/dL \[\<3.0 mmol/L\]) as measured by continuous glucose monitoring, 4 weeks|Adrenaline response to hypoglycemia, Change from baseline peak adrenaline after glucose nadir as measured during the hyperinsulinemic hypoglycemic clamp, 4 weeks|Growth hormone response to hypoglycemia, Change from baseline peak growth hormone after glucose nadir as measured during the hyperinsulinemic hypoglycemic clamp, 4 weeks|Cortisol response to hypoglycemia, Change from baseline peak cortisol after glucose nadir as measured during the hyperinsulinemic hypoglycemic clamp, 4 weeks|Glucose requirement to correct hypoglycemia, Change from baseline glucose infusion requirement after glucose nadir to correct hypoglycemia during the hyperinsulinemic hypoglycemic clamp, 4 weeks|Lipid profile, Change from baseline lipid profile as measured by blood assay, 4 weeks|Systolic blood pressure, Change from baseline systolic blood pressure as measured by digital sphygmomanometer, 4 weeks|Diastolic blood pressure, Change from baseline diastolic blood pressure as measured by digital sphygmomanometer, 4 weeks|Prandial GLP1 secretion, Change from baseline GLP1 area under the curve (AUC) during mixed meal tolerance test (MMTT), 4 weeks|Prandial GIP secretion, Change from baseline GIP area under the curve (AUC) during mixed meal tolerance test (MMTT), 4 weeks
|
